ubet63 link login register
ubet63 link login register
DUBLÍN--(BUSINESS WIRE)--dic. 18, 2024-- GC Aesthetics® (GCA), una empresa privada de tecnología médica que ofrece soluciones estéticas y de reconstrucción para los mercados sanitarios mundiales, se enorgullece de anunciar el inicio de un importante estudio clínico multicéntrico y prospectivo en Europa para evaluar, y confirmar, la seguridad, eficacia y satisfacción de las pacientes asociadas al innovador implante mamario redondo liso opaco PERLETM. Este comunicado de prensa trata sobre multimedia. Ver la noticia completa aquí: https://www.businesswire.com/news/home/20241218698944/es/ GC Aesthetics' Perle Breast Implant feature a proprietary surface technology (BioQTM) and GCA’s industry-leading gel technology (EmunomicTM Breast Tissue Dynamic Gel). Este amplio estudio reúne a destacados cirujanos del Servicio Nacional de Salud (NHS, por sus siglas en inglés) y de clínicas privadas del Reino Unido, así como de consultas privadas de toda Europa, lo que garantiza un conjunto de datos sólido y diverso que aborda indicaciones tanto cosméticas como reconstructivas. "Mediante la generación de evidencia clínica de alta calidad, nuestro objetivo es brindar información sin precedentes sobre el rendimiento y los beneficios para el paciente del implante PERLETM, estableciendo un nuevo estándar para la tecnología de implantes mamarios y la atención al paciente", dijo Chris Brotherston, jefe de QA / RA y asuntos clínicos de GC Aesthetics. PERLETM es una línea muy innovadora de implantes mamarios opacos lisos que cuentan con una tecnología de superficie patentada (BioQTM), la tecnología de gel líder del sector de GCA (EmunomicTM Breast Tissue Dynamic Gel), además de una versión mejorada de las características de seguridad que han sustentado el excelente historial de seguridad de GCA a largo plazo. "PERLETM es un implante único e innovador y los datos a largo plazo sobre seguridad y eficacia ayudarán a pacientes y médicos a tomar decisiones informadas con confianza. El estudio PERLETM implica una recopilación de datos sólida y exhaustiva con una muestra de gran tamaño", comentó Nabila Nasir, cirujana de mama y oncoplástica MBBS, BSc, FRCS. Compromiso estratégico con la innovación y las soluciones basadas en la evidencia "Este estudio demuestra el enfoque de GCA hacia el crecimiento sostenible y la creación de valor a través de la innovación validada clínicamente. Los resultados no solo fortalecerán nuestra cartera de productos, sino que también reforzarán la reputación de GCA de ofrecer soluciones de alta calidad, seguras y centradas en el paciente. Al invertir en investigación clínica rigurosa y a largo plazo, GCA sigue posicionándose como un socio de confianza para los profesionales sanitarios y las mujeres de todo el mundo", concluyó Carlos Reis Pinto, director general de GC Aesthetics. Como parte del enfoque estratégico de GCA en la innovación y los avances clínicos basados en la evidencia, este estudio pone de relieve el compromiso de satisfacer las necesidades cambiantes de pacientes y cirujanos de todo el mundo. El texto original en el idioma fuente de este comunicado es la versión oficial autorizada. Las traducciones solo se suministran como adaptación y deben cotejarse con el texto en el idioma fuente, que es la única versión del texto que tendrá un efecto legal. Vea la versión original en businesswire.com : https://www.businesswire.com/news/home/20241218698944/es/ CONTACT: Fara Naomi Macias Director de marketing - GCA faramacias@gcaesthetics.com press@gcaesthetics.com KEYWORD: EUROPE IRELAND UNITED KINGDOM INDUSTRY KEYWORD: WOMEN SURGERY HEALTH MEDICAL DEVICES HEALTH TECHNOLOGY CONSUMER CLINICAL TRIALS OTHER HEALTH SOURCE: GC Aesthetics Copyright Business Wire 2024. PUB: 12/18/2024 05:12 PM/DISC: 12/18/2024 05:11 PM http://www.businesswire.com/news/home/20241218698944/es
Moment of silence for former President Jimmy Carter held before the Falcons-Commanders game
TAMPA, Fla. (AP) — Tampa Bay’s bid for a fourth straight NFC South title and fifth consecutive playoff berth is gaining momentum. Back-to-back wins over a pair of last-place teams , combined with Atlanta’s three-game losing streak, have propelled the Bucs (6-6) to a tie atop the division. Although the Falcons (6-6) hold a tiebreaker after sweeping the season series between the teams, Tampa Bay can control its own destiny by finishing strong against a less than imposing schedule. The Bucs, who are back in the thick of the race after beating the New York Giants and Carolina Panthers, figure to be favored in four of their five remaining games. “Every week, we said it’s a playoff game, we got to take care of us. It’s not going to be easy. As it was (Sunday), it’s going to be a dog fight every week,” coach Todd Bowles said after Sunday’s 26-23 overtime win at Carolina. “We got to clean up some things, we know that, but it’s hard to win in this league,” the coach said of the mistake-filled victory that lifted the Bucs back to .500. “We’ll take a win any way we can get it.” After facing Las Vegas (2-10) this week, the Bucs will finish with road games against the Los Angeles Chargers (8-4) and Dallas Cowboys (5-7), followed by home dates vs. Carolina (3-9) and the New Orleans Saints (4-8). RELATED COVERAGE 49ers are nearing rock bottom following a blowout loss and the injury to McCaffrey Jim Harbaugh’s Chargers are in good position for the playoffs but need to improve on offense The Vikings are showing their worth at 10-2 by winning the games that don’t go smoothly What’s working Kicker Chase McLaughlin has been one of team’s most consistent performers, converting 21 of 23 field goal attempts. He was 4 of 5 against the Panthers, including 51-yarder to force overtime on the final play of regulation. He missed from 55 yards in OT before winning it with a 30-yard field goal on Tampa Bay’s next possession. What needs help Just when it appeared the defense was beginning to trend in the right direction, Carolina’s Bryce Young threw for 298 yards without an interception against the Bucs in one of his better outings of the season. “In the first half, he did it with his feet and the second half he did it with his arm,” Bowles said. The AP Top 25 college football poll is back every week throughout the season! Get the poll delivered straight to your inbox with AP Top 25 Poll Alerts. Sign up here . Stock up Running back Bucky Irving rushed for a career-best 152 yards and finished with 185 from scrimmage against Carolina, making him the first rookie since Miles Sanders in 2019 to have consecutive games with 150-plus yards from scrimmage. Stock down A week after playing well offensively and defensively in a 23-point rout of the New York Giants, the Bucs were sloppy against the Panthers. In addition to throwing two interceptions, Mayfield was sacked four times. Tampa Bay was penalized seven times for 54 yards, and the defense was only able to sack Young once. Injuries Mayfield (sore leg), linebacker K.J. Britt (sprained ankle) and safety Mike Edwards (hamstring) will be on the injury report this week. Bowles said he’s not sure what Mayfield’s practice status will be when the team reconvenes Wednesday, however he expects the quarterback to play Sunday. Key numbers 37 and 101 — Wide receiver Mike Evans had another big day against Carolina, posting the 37th 100-yard receiving performance of his career — fifth among active players. He also moved ahead of Hall of Famers Steve Largent and Tim Brown for sole possession of ninth place on the all-time list for TD receptions with 101. Next steps The Buccaneers host Las Vegas in Tampa Bay’s first home game in a month and the third consecutive outing against a last-place team. The Raiders (2-10) have lost eight in a row. ___ NFL: https://apnews.com/hub/nfl
( MENAFN - Jordan Times) LONDON - During the Irish famine in the 1840s, as more than one million Irish citizens died, vast quantities of food were exported from Ireland to Britain. For the Whig government in London, the defence of commercial interests, the dictates of laissez-faire economics and Political indifference to Irish suffering trumped any obligation to prevent mass starvation by intervening in markets. The international response to the COVID-19 pandemic bears a discomfiting resemblance to the British response to the Irish famine. Although science and industry have given us the means to immunise the world, nine months after the first arm was jabbed with a COVID-19 vaccine, rich countries are using their market power to direct doses away from poor countries, placing millions of lives at risk. Consider some recent actions by the European Union. Under a contract with Johnson & Johnson (J&J), the bloc has imported millions of vaccine doses from a company in South Africa, a country where a mere 11 per cent of the population is vaccinated and the Delta variant is fuelling a surge in cases. Yet efforts to divert vaccine exports from Europe to South Africa and its neighbours were met with a display of vaccine gunboat diplomacy, with the EU threatening to take action under a clause in the J&J contract prohibiting export restrictions. The message to the world was clear. While EU commissioners and political leaders may arrive at UN meetings waxing lyrical about the importance of international cooperation and global vaccine equity, the iron fist of vaccine nationalism is driving real-world policy. When it comes to weighing African lives against marginal gains in the health of already-protected EU citizens, Africans come in a distant second. Former UK Prime Minister Gordon Brown recently highlighted the South Africa example as a“shocking symbol” of global vaccine injustice. He was right, but the injustice is global. In a world that has delivered more than five billion doses, over 70 per cent of people in rich countries have now received at least one jab, compared to only 1.8 per cent in the poorest countries. This is an equity gap that kills. We know that vaccinations provide effective protection against COVID-19 deaths and hospitalisation. As US President Joe Biden has reminded Americans, this is a“pandemic of the unvaccinated”. The same is true globally. Nevertheless, the United States and other rich countries are now preparing to deliver vaccine booster shots to already-protected populations facing marginal health risks, effectively diverting supplies from countries where access to vaccines is, quite literally, a matter of life and death. The current distribution of vaccines is not just ethically indefensible. It is also epidemiologically short-sighted and economically ruinous. Leaving large swaths of the world unvaccinated increases the risk that vaccine-resistant viral mutations will emerge, effectively prolonging the pandemic and endangering people everywhere. Meanwhile, expanding vaccinations would boost economic recovery, adding $9 trillion to global output by 2025, according to an estimate by the International Monetary Fund, and help prevent major reversals in poverty, health and education. Basic arithmetic shows that we can vaccinate the world. Estimates by the data analytics firm Airfinity suggest that around 12 billion vaccine doseswill be produced in 2021, with output doubling in 2022. That's more than enough to achieve the international target of 40 per cent coverage by the end of this year and 60-70 per cent by mid-2022. Unfortunately, it is not enough to achieve the targets while satisfying rich countries' desire to hoard surplus stocks. With their current contracts, rich countries could achieve full vaccination coverage rates for over 80 per cent of their populations, including boosters for vulnerable people, and have a surplus of 3.5 billion doses, according to the Airfinity data, enough to cover the deficit in poor countries and still leave rich countries with a healthy contingency reserve. Instead, rich countries are actively undermining international cooperation efforts. Aid donors have invested $10 billion in the COVID-19 Vaccine Global Access (COVAX) facility, the international program designed to provide vaccines to the world's poorest countries. That financing has secured contracts for around two billion doses. Additionally, the World Bank has provided $4 billion for COVAX and an African Union vaccine-purchase initiative. But COVAX and poor countries are constantly pushed to the back of the line for supplies from vaccine manufacturers for whom rich countries come first, not least because of their governments' threats to take legal action and impose penalties. The pandemic has demonstrated that the world needs a more efficient and equitable distribution of vaccine-production capabilities. Developing these capabilities will require knowledge-sharing, technology transfer, intellectual-property waivers, and long-term investment. But without immediate and decisive action to replace the trickle-down approach to vaccine provision with market redistribution, John Maynard Keynes's dictum that“in the long run we are all dead” will have a tragic resonance. There are three priorities. First, vaccine delivery must be aligned with the target of 40 per cent coverage in all countries by the end of this year. Rich countries must agree to adjust their own schedules so that vaccine manufacturers can make deliveries for COVAX and developing countries. Building surplus stocks in rich countries while allowing people to die for want of vaccines in poor countries is indefensible. Aid donors should also provide the additional $3.8 billion in grant financing needed to trigger COVAX options on an additional 760 million doses by the end of 2021. Second, to meet the international targets, we need to move beyond intermittent vaccine donations to large-scale, coordinated dose-sharing. The EU, the United Kingdom, and the US should immediately share an additional 250 million doses, less than one-quarter of their collective surplus, through COVAX by the end of September, with a clear schedule for providing an additional one billion doses by early 2022. Third, beyond vaccine equity, there is an urgent need to strengthen health systems, not just through the provision of medical oxygen, which is in critically short supply, therapeutics, and diagnostic equipment, but also by investing in the health workers and infrastructure needed to get vaccines into arms. The current gap between funds pledged and funds allocated for this purpose is around $16.6 billion. Our ability to save lives, restore hope, and rebuild economies shattered by the pandemic is constrained not by a shortage of vaccines or financing, but also by a deficit of justice and international cooperation. The governments of rich countries often recite the mantra that“no one is safe until everyone is safe”. Their leaders must now act like they believe it. Kevin Watkins, a former CEO of Save the Children UK, is a visiting professor at the Firoz Lalji Institute for Africa at the London School of Economics. Copyright: Project Syndicate, 2021. MENAFN02122024000028011005ID1108949054 Legal Disclaimer: MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.
- Previous:
- Next: ubet63 link register
